Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

6 Dec 2022

Abstract excerpt

Nilotinib is a tyrosine kinase inhibitor that is safe and tolerated in neurodegeneration, it achieves CSF concentration that is adequate to inhibit discoidin domain receptor (DDR)-1. Nilotinib significantly affects dopamine metabolites, including Homovanillic acid (HVA), resulting in an increase in brain dopamine. HD is a hereditary disease caused by mutations in the Huntingtin’s (HTT) gene and characterized by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Genetic Neurodegenerative Diseases
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36557263
DOI: 10.3390/metabo12121225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease PatientsPMID 36557263Read ↗

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib induces autophagy and reduces inflammation and vascular fibrosis in Alzheimer’s diseaseSemantic proximity Read ↗

Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's diseaseSemantic proximity Read ↗

Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseasesSemantic proximity Read ↗

Therapy development in Huntington disease: From current strategies to emerging opportunitiesSemantic proximity Read ↗

DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.Semantic proximity Read ↗

The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s DiseaseSemantic proximity Read ↗

Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s diseaseSemantic proximity Read ↗

Dysfunctional striatal dopamine signaling in Huntington's diseaseSemantic proximity Read ↗

Molecular Imaging Markers to Track Huntington’s Disease PathologySemantic proximity Read ↗

Safety and feasibility of research lumbar puncture in Huntington’s disease: the HDClarity cohort and bioresourceSemantic proximity Read ↗

Antidepressants and Slower Disease Progression in Huntington’s DiseaseSemantic proximity Read ↗

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.